Product Description
VIO-01 is the second candidate harnessed from Valerio’s propriety platform of DNA decoy therapeutics and is designed to be a next-generation pan-DDR DNA decoy.While PARP inhibitors have been a significant advance in cancer treatment, the class still has several limiting factors, particularly the rapid onset of resistance. As a next-generation pan-DDR DNA decoy, VIO-01 is designed to abrogate several DNA repair pathways and trigger a robust immune response by activating the innate immune response through the STING pathway. The STING pathway plays a critical role in detecting DNA abnormalities and activating the immune system to target and destroy cancer cells. (Sourced from: https://valeriotx.com/our-science/#pipeline)
Mechanisms of Action: PARP Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Valerio Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Cancer|Ovarian Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VIO-01-101 | P2 |
Recruiting |
Breast Cancer|Ovarian Cancer|Prostate Cancer |
2026-01-29 |